Study on the Effects of Thymalfasin Combined with 2HRZE/4HR on Immune Cells in Patients with Pulmonary Tuberculosis
Objective:To investigate the effects of thymalfasin combine with 2HRZE/4HR on immune cells in patients with pulmonary tuberculosis.Method:160 patients with pulmonary tuberculosis admitted to Jiangxi Chest Hospital from January 2022 to January 2023 were selected as the research subjects.According to different treatment plans,it were divided into an observation group and a control group,with 80 cases in each group.The control group was treated with the 2HRZE/4HR regimen,while the observation group was treated with thymalfasin in addition to the control group.Compared the clinical efficacy,T lymphocyte subsets,negative conversion rate of sputum bacterial,and adverse reactions between two groups.Result:The total effective rate of the observation group was 92.50%,which was higher than the control group's 87.5%,and the difference was not statistically significant(P＞0.05).After treatment,the levels of CD3+,CD4+,CD8+ and CD4+/CD8+in both groups increased,and the observation group was higher than the control group(P＜0.05).After 2 months of treatment,there was no significant difference in the negative conversion rate of sputum bacteria between the two groups(P＞0.05).After 4 month and 6 month of treatment,the negative conversion rate of sputum bacteria in the observation group was higher than that in the control group(P＜0.05).The incidence of adverse reactions in the observation group was 8.75%,lower than the 22.50%in the control group(x2=5.736,P=0.017).Conclusion:Thymalfasin combined with 2HRZE/4HR regimen for the treatment of pulmonary tuberculosis patients can greatly improve clinical efficacy and patient immune function,have fewer adverse reactions.
万方数据
